companydata.dkCABA APS: Financial statements 2024
CVR: 39691825
CABA APS (CVR 39691825) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity amounted to DKK 28,125. The solvency ratio was 56.3%.
- Gross Profit
- -3,125 kr.
- Profit/Loss
- -3,125 kr.
- Equity
- 28,125 kr.
- Total Assets
- 50,000 kr.
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -3 t. | -3 t. | 28 t. | 0 |
| 2023 | - | -3 t. | -3 t. | 31 t. | 0 |
| 2022 | - | -3 t. | -3 t. | 34 t. | 0 |
| 2021 | - | -3 t. | -3 t. | 38 t. | 0 |
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
How creditworthy is CABA APS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
CABA APS has published its annual report for 2023. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
About CABA APS
CABA APS is a Danish company of the type Anpartsselskab based in Fårevejle, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ACBA APS. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company is owned by Devopharma ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity amounted to DKK 25,000.